5 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
iABC Programme (IABC PROGRAMME)
Date du début: 1 août 2015, Date de fin: 31 juil. 2020,
Cystic Fibrosis (CF) is a common fatal inherited disease with a frequency of 1 in 2500 live births, affecting approximately 36,000 (0.737/10,000) people in the EU. Chronic bacterial pulmonary infection leading to an irreversible decline in lung structure and function is the main cause of mortality and morbidity in patients with CF, with more than 95% of deaths due to respiratory failure. Pseudomon ...
Voir le projet
21
Participants partenaires
TERMINÉ
Clinical safety, immunogenicity and efficacy of a therapeutic vaccine that combines peptides mimicking antigen receptors on autoimmune B and T cells associated with myasthenia gravis (Myasterix)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,
The MYASTERIX project will advance a therapeutic vaccine candidate (designated orphan drug) indicated for the autoimmune disease myasthenia gravis (MG) to clinical proof of concept studies. MG is caused by T cell dependent antibodies that bind to and deplete acetylcholine receptors (AChR) at neuromuscular junctions causing muscle weakness by interfering with neuromuscular transmission and junction ...
Voir le projet
6
Participants partenaires
TERMINÉ
QUantitative Imaging in Cancer: CONnecting CEllular Processes with Therapy (QUIC-CONCEPT)
Date du début: 1 sept. 2011, Date de fin: 31 déc. 2017,
The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proliferation, apoptosis, and necrosis, to allow drug developers to demonstrate reliably modulation of these pathologic processes in tumours in patients in realistic trials. Our vision for January 2016 is that drug developers can incorporate these IBs for decision- ...
Voir le projet
26
Participants partenaires
TERMINÉ
Management of Hypotension In the Preterm Extremely Low Gestational Age Newborn (THE HIP TRIAL)
Date du début: 1 oct. 2010, Date de fin: 30 sept. 2017,
Assuming an annual birth rate of 10.25 births/1,000 population approximately 25,000 Extremely Low Gestational Age Newborns are born every year in the EU. Conservative figures estimate that approximately half of all these babies will develop low blood pressure and require treatment. However, no uniform criteria exist to define hypotension and the evidence to support our current management strategie ...
Voir le projet
17
Participants partenaires
TERMINÉ
Bioactive Implantable Polymers based on UreidoPyrimidinone (BIP-UPy)
Date du début: 1 févr. 2013, Date de fin: 31 janv. 2017,
BIP-UPy addresses the need for biomedical implants which can be easily fine-tuned in their properties in regards to bioactivity, biodegradability, and mechanical performance, and thereby be optimized for their targeted clinical application.This project will develop a library comprising of a selection of synthetic polymers and specific bioactivities which can be used to provide the required propert ...
Voir le projet